Monopar Therapeutics
MNPR
82 hedge funds and large institutions have $342M invested in Monopar Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 11 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
11% more funds holding
Funds holding: 74 → 82 (+8)
10.61% more ownership
Funds ownership: 82.71% → 93.32% (+11%)
5% less capital invested
Capital invested by funds: $361M → $342M (-$19.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$10.5M |
| 2 |
DM
Deerfield Management
New York
|
+$9.25M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.31M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.23M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.12M |
| 4 |
Millennium Management
New York
|
-$1.43M |
| 5 |
Citigroup
New York
|
-$822K |
MNPR Hedge Fund Activity: Q1 2026 in Review
82 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2026, worth a combined $342M — down 5.3% from $361M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MNPR positions and 11 closed out — a net gain of 9 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $10.5M. The largest seller was Adage Capital Partners, cutting an estimated $20M.
- 82 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2026, up from 74 in Q4 2025.
- Funds reported $342M of Monopar Therapeutics stock for Q1 2026, down 5.3% quarter-over-quarter.
- 20 funds opened new Monopar Therapeutics positions in Q1 2026 and 11 closed out, a net change of +9 holders.
- The largest Monopar Therapeutics buyer in Q1 2026 was Sio Capital Management, an estimated $10.5M added.
- The largest Monopar Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $20M sold.
Based on aggregated 13F filings for Q1 2026.